WO2021054531A2 - Stabilized efinaconazole-containing pharmaceutical composition comprising antioxidant - Google Patents

Abstract

The present invention provides an efinaconazole-containing solution-type topically-administered pharmaceutical composition comprising a specific antioxidant. The pharmaceutical composition of the present invention has excellent physicochemical stability.

Description

Stabilized efinaconazole-containing pharmaceutical composition comprising an antioxidant

The present invention relates to a pharmaceutical composition for topical administration in the form of a solution containing efinaconazole. More specifically, it relates to efinaconazole-containing pharmaceutical compositions for topical administration in the form of a solution containing a specific antioxidant.

Epinaconazole is a triazole-based antifungal agent having the structure of the following formula (1), and its chemical name is (2R,3R)-2-(2,4-difluorophenyl)-3-(4-methylenepiperidine- 1-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol[(2R,3R)-2-(2,4-difluorophenyl)-3-(4- methylenepiperidin-1-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol].

<Formula 1>

Epinaconazole has the activity of inhibiting lanosterol 14α-demethylase in the ergosterol biosynthetic pathway, and a 10% topical solution formulation for the treatment of onychomycosis (trade names: JUBLIA ^TM , Kaken Pharmaceutical Co., Ltd.). The topical solution formulation, together with efinaconazole, may contain ethanol as a volatile solvent; Cyclomethicone as a wetting agent; And diisopropyl adipate and C ₁₂ -C ₁₅ alkyl lactate as non-volatile solvents (US Pat. Nos. 7,214,506, 8,039,494, 8,486,978, 9,302,009, 9,566,272, 9,861,698, and 9,877,955, etc.).

Solution formulations containing efinaconazole have a problem of stability, that is, discoloration within a short storage period resulting in a composition color ranging from yellow to dark red or brown. In order to solve this stability problem, U.S. Patent No. US 9,662,394 and International Patent Publication No. WO 2015/051183 disclose specific combinations of chelating agents, antioxidants, and acids, namely ethylenediaminetetraacetic acid (EDTA) or a salt thereof, butyl. A liquid or semi-solid composition comprising butylated hydroxytoluene (BHT), and citric acid has been disclosed.

The present inventors have conducted various studies to develop a formulation for topical administration in the form of a solution containing efinaconazole. In particular, the present inventors have studied combinations of various chelating agents, antioxidants, and acids in order to develop a formulation that can effectively improve physicochemical stability problems such as discoloration. As a result, it was found that when the formulation was carried out by combining a specific antioxidant with ethylenediaminetetraacetic acid or its sodium salt and citric acid, more excellent physicochemical stability could be secured compared to known formulations.

Accordingly, an object of the present invention is to provide a pharmaceutical composition for topical administration in the form of a solution containing efinaconazole, comprising a combination of a specific antioxidant, ethylenediaminetetraacetic acid or its sodium salt, and citric acid.

According to one aspect of the invention, efinaconazole; ethanol; Cyclomethicone; _{Diisopropyl adipate, C 12} -C ₁₅ alkyl lactate, or mixtures thereof as non-volatile solvents; Ethylenediaminetetraacetic acid or its sodium salt as a chelating agent; Antioxidants; And a pharmaceutical composition for topical administration in the form of a solution containing citric acid as an acid, wherein the antioxidant is selected from the group consisting of palmitic acid, chlorogenic acid, and linoleic acid. Is provided.

In the pharmaceutical composition of the present invention, the antioxidant may be present in an amount of 0.01 to 2% by weight, preferably 0.1 to 1% by weight, more preferably about 0.1% by weight, based on the total weight of the composition.

When the formulation is carried out by combining a specific antioxidant, that is, palmitic acid, chlorogenic acid, and/or linoleic acid with ethylenediaminetetraacetic acid or its sodium salt and citric acid, an efinaconazole-containing pharmaceutical composition having excellent physicochemical stability is obtained. It has been found by the present invention. Therefore, the pharmaceutical composition of the present invention can be usefully used as a formulation for topical administration having excellent stability.

The present invention is efinaconazole; ethanol; Cyclomethicone; _{Diisopropyl adipate, C 12} -C ₁₅ alkyl lactate, or mixtures thereof as non-volatile solvents; Ethylenediaminetetraacetic acid or its sodium salt as a chelating agent; Antioxidants; And a pharmaceutical composition for topical administration in the form of a solution containing citric acid as an acid, wherein the antioxidant is selected from the group consisting of palmitic acid, chlorogenic acid, and linoleic acid. Provides.

The pharmaceutical composition of the present invention contains efinaconazole as an active ingredient. Epinaconazole may be contained in therapeutically effective amounts, for example, 8 to 12% by weight, preferably about 10% by weight, based on the total weight of the composition, but It is not limited.

The pharmaceutical composition of the present invention comprises a combination of certain antioxidants and ethylenediaminetetraacetic acid or its sodium salt and citric acid. The antioxidant, i.e. palmitic acid, chlorogenic acid, and/or linoleic acid, is 0.01 to 2% by weight, preferably 0.1 to 1% by weight, more preferably based on the total weight of the composition. It may be present in an amount of about 0.1% by weight.

The chelating agent, that is, ethylenediaminetetraacetic acid (EDTA) or its sodium salt and citric acid may be used in an amount sufficient to ensure stability. For example, ethylenediaminetetraacetic acid (EDTA) or its sodium salt may be present in an amount of 0.0001 to 1.5% by weight, preferably 0.0001 to 0.0025% by weight, more preferably about 0.00025% by weight, based on the total weight of the composition. Citric acid may be present in an amount of 0.05 to 0.25% by weight, preferably about 0.1% by weight, based on the total weight of the composition.

The pharmaceutical composition of the present invention comprises ethanol as a volatile solvent; Cyclomethicone as a wetting agent; Non-volatile solvents include diisopropyl adipate, C ₁₂ -C ₁₅ alkyl lactate, or mixtures thereof. The volatile solvent, wetting agent, and non-volatile solvent may be used in an amount used in a conventional efinaconazole-containing solution formulation (eg, US Patent No. US 9,662,394, etc.). For example, ethanol may be present in an amount of 50 to 65% by weight, preferably about 53.79975% by weight, based on the total weight of the composition. For example, the cyclomethicone may be present in an amount of 10 to 15% by weight, preferably about 13% by weight based on the total weight of the composition. For example, diisopropyl adipate may be present in an amount of 8 to 15% by weight, preferably about 12% by weight, based on the total weight of the composition. For example, the C ₁₂ -C ₁₅ alkyl lactate may be present in an amount of 8 to 15% by weight, preferably about 10% by weight, based on the total weight of the composition. In addition, if necessary, the pharmaceutical composition of the present invention may further contain a small amount of water (for example, 5% by weight or less, preferably about 1% by weight).

In one embodiment, 8-12% by weight of efinaconazole; Ethanol 50-65% by weight; 10 to 15% by weight of cyclomethicone; 8-15% by weight of diisopropyl adipate; 8-15% by weight of C ₁₂ -C _{15 alkyl lactate;} 0.0001 to 1.5% by weight of ethylenediaminetetraacetic acid or its sodium salt; 0.01 to 2% by weight of an antioxidant selected from the group consisting of palmitic acid, chlorogenic acid, and linoleic acid; From 0.05 to 0.25% by weight of citric acid; And there is provided a pharmaceutical composition comprising 0 to 5% by weight of water.

In another embodiment, 10% by weight efinaconazole; 53.79975% ethanol by weight; 13% by weight cyclomethicone; 12% by weight of diisopropyl adipate; 10% by weight of C ₁₂ -C _{15 alkyl lactate;} 0.00025% by weight of ethylenediaminetetraacetic acid or sodium salt thereof; 0.1% by weight of an antioxidant selected from the group consisting of palmitic acid, chlorogenic acid, and linoleic acid; 0.1% citric acid; And there is provided a pharmaceutical composition consisting of 1% by weight of water.

The pharmaceutical composition of the present invention can be prepared by mixing according to a conventional method using the above ingredients. If necessary, a stock solution containing a chelating agent and a stock solution containing efinaconazole are prepared, respectively, and then appropriately mixed with other ingredients to form a solution, thereby preparing the pharmaceutical composition of the present invention.

Hereinafter, the present invention will be described in more detail through Examples and Test Examples. However, these Examples and Test Examples illustrate the present invention, and the present invention is not limited thereto.

Example 1. Preparation of solution and evaluation of stability

(1) Preparation of solution

According to the components and contents of Tables 1 and 2 below, a solution containing efinaconazole was prepared. The content of each component in Tables 1 and 2 represents the weight% in the solution. A stock solution was prepared by dissolving ethylenediaminetetraacetic acid disodium salt (EDTA disodium) in purified water at a concentration of 0.025 mg/mL. In addition, efinaconazole (0.2 g) was dissolved in ethanol (0.076 g) to prepare an efinaconazole-containing stock solution. In an efinaconazole-containing ethanol solution, cyclomethicone, diisopropyl adipate, C ₁₂ -C ₁₅ alkyl lactate (Ashland), antioxidants (monothioglycerol, palmitic acid, tertiary-butylhydroquinone (TBHQ) ), chlorogenic acid, linoleic acid, N-acetyl-L-cysteine, benzotriazole, thioglycolic acid, epigallocatechin gallate, or 2-mercaptobenzimidazole), citric acid, and EDTA disodium (in stock solution form Addition) was sequentially added and mixed to prepare a solution containing efinaconazole.

	Formulation Example (% by weight)
	1-1	1-2	1-3	1-4	1-5
Epinaconazole	10	10	10	10	10
ethanol	53.79975	53.79975	53.79975	53.79975	53.79975
Cyclomethicone	13	13	13	13	13
Diisopropyl adipate	12	12	12	12	12
C 12 -C 15 alkyl lactate	10	10	10	10	10
EDTA disodium	0.00025	0.00025	0.00025	0.00025	0.00025
Monothioglycerol	0.1
Palmitic acid		0.1
Tertiary-butylhydroquinone			0.1
Chlorogenic acid				0.1
Linoleic acid					0.1
Purified water	One	One	One	One	One
Citric acid	0.1	0.1	0.1	0.1	0.1
Sum(%)	100	100	100	100	100

	Formulation Example (% by weight)
	1-6	1-7	1-8	1-9	1-10
Epinaconazole	10	10	10	10	10
ethanol	53.79975	53.79975	53.79975	53.79975	53.79975
Cyclomethicone	13	13	13	13	13
Diisopropyl adipate	12	12	12	12	12
C 12 -C 15 alkyl lactate	10	10	10	10	10
EDTA disodium	0.00025	0.00025	0.00025	0.00025	0.00025
N-acetyl-L-cysteine	0.1
Benzotriazole		0.1
Thioglycolic acid			0.1
Epigallocatechin gallate				0.1
2-mercaptobenzimidazole					0.1
Purified water	One	One	One	One	One
Citric acid	0.1	0.1	0.1	0.1	0.1
Sum(%)	100	100	100	100	100

(2) Stability evaluation

The solutions prepared in Formulation Examples 1-1 to 1-10 were stored at 65° C. for 4 weeks, respectively, and then absorbance at 500 nm and 600 nm of the solution was measured. As a control formulation, JUBLIA ^™ (containing 10% efinaconazole-topical solution formulation, EDTA disodium, butylated hydroxytoluene (BHT), and citric acid, Kaken Pharmaceutical Co., Ltd.) was used. The results are shown in Table 3 below.

Formulation example	EDTA disodium/antioxidant/citric acid	Absorbance
		500 nm	600 nm
1-1	Monothioglycerol	0.100	0.033
1-2	Palmitic acid	0.007	0.004
1-3	Tertiary-butylhydroquinone (TBHQ)	0.048	0.006
1-4	Chlorogenic acid	0.014	0.008
1-5	Linoleic acid	0.012	0.008
1-6	N-acetyl-L-cysteine	0.152	0.062
1-7	Benzotriazole	0.100	0.043
1-8	Thioglycolic acid	0.070	0.039
1-9	Epigallocatechin gallate	0.368	0.138
1-10	2-mercaptobenzimidazole	0.070	0.025
Control formulation	Butylated hydroxytoluene	0.022	0.017

From the results of Table 3, the solution obtained using palmitic acid (Formulation Example 1-2), chlorogenic acid (Formulation Example 1-4), and linoleic acid (Formulation Example 1-5) among various antioxidants was about It can be seen that it has remarkably excellent stability by showing a low absorbance value of 50% or more.

Example 2. Preparation of solution and evaluation of stability

(1) Preparation of solution

According to the components and contents of Tables 4 to 6 below, a solution containing efinaconazole was prepared in the same manner as in Example 1 (1). The content of each component in Tables 4 to 6 represents the weight percent of the solution.

	Formulation Example (% by weight)
	2-1	2-2	2-3	2-4	2-5	2-6	2-7
Epinaconazole	10	10	10	10	10	10	10
ethanol	62.79975	56.79975	50.79975	62.79975	50.79975	62.79975	60.79975
Cyclomethicone	10	12	14	10	14	10	14
Diisopropyl adipate	8	11	13	8	13	8	13
C 12 -C 15 alkyl lactate	8	9	11	8	11	8	11
EDTA disodium	0.00025	0.00025	0.00025	0.00025	0.00025	0.00025	0.00025
Palmitic acid	0.1	0.1	0.1
Chlorogenic acid				0.1	0.1
Linoleic acid						0.1	0.1
Purified water	One	One	One	One	One	One	One
Citric acid	0.1	0.1	0.1	0.1	0.1	0.1	0.1
Sum(%)	100	100	100	100	100	100	100

	Formulation Example (% by weight)
	2-8	2-9	2-10	2-11	2-12	2-13	2-14
Epinaconazole	10	10	10	10	10	10	10
ethanol	53.7999	53.799	53.7975	53.7999	53.7975	53.7999	53.7975
Cyclomethicone	13	13	13	13	13	13	13
Diisopropyl adipate	12	12	12	12	12	12	12
C 12 -C 15 alkyl lactate	10	10	10	10	10	10	10
EDTA disodium	0.0001	0.001	0.0025	0.0001	0.0025	0.0001	0.0025
Palmitic acid	0.1	0.1	0.1
Chlorogenic acid				0.1	0.1
Linoleic acid						0.1	0.1
Purified water	One	One	One	One	One	One	One
Citric acid	0.1	0.1	0.1	0.1	0.1	0.1	0.1
Sum(%)	100	100	100	100	100	100	100

	Formulation Example (% by weight)
	2-15	2-16	2-17	2-18	2-19	2-20	2-21
Epinaconazole	10	10	10	10	10	10	10
ethanol	53.88975	53.39975	52.89975	53.88975	52.89975	53.88975	52.89975
Cyclomethicone	13	13	13	13	13	13	13
Diisopropyl adipate	12	12	12	12	12	12	12
C 12 -C 15 alkyl lactate	10	10	10	10	10	10	10
EDTA disodium	0.00025	0.00025	0.00025	0.00025	0.00025	0.00025	0.00025
Palmitic acid	0.01	0.5	One
Chlorogenic acid				0.01	One
Linoleic acid						0.01	One
Purified water	One	One	One	One	One	One	One
Citric acid	0.1	0.1	0.1	0.1	0.1	0.1	0.1
Sum(%)	100	100	100	100	100	100	100

(2) Stability evaluation

After storing the solutions prepared in Formulation Examples 2-1 to 2-21 at 65° C. for 4 weeks, respectively, the absorbance was measured in the same manner as in Example 1 (2). The results are shown in Table 7 below.

Formulation example	Absorbance
	500 nm	600 nm
2-1	0.010	0.005
2-2	0.007	0.003
2-3	0.007	0.003
2-4	0.015	0.008
2-5	0.015	0.009
2-6	0.013	0.009
2-7	0.011	0.008
2-8	0.010	0.006
2-9	0.007	0.004
2-10	0.007	0.005
2-11	0.015	0.010
2-12	0.013	0.008
2-13	0.013	0.008
2-14	0.012	0.008
2-15	0.010	0.006
2-16	0.007	0.004
2-17	0.006	0.004
2-18	0.014	0.009
2-19	0.013	0.008
2-20	0.012	0.008
2-21	0.011	0.007
Control formulation	0.022	0.017

From the results of Table 7, it can be seen that the solution obtained using palmitic acid, chlorogenic acid, and linoleic acid as antioxidants has excellent stability.

Claims (6)

1. Efinaconazole; ethanol; Cyclomethicone; _{Diisopropyl adipate, C 12} -C ₁₅ alkyl lactate, or mixtures thereof as non-volatile solvents; Ethylenediaminetetraacetic acid or its sodium salt as a chelating agent; Antioxidants; And in the pharmaceutical composition for topical administration in the form of a solution containing citric acid as an acid,

   The pharmaceutical composition for topical administration in the form of a solution, characterized in that the antioxidant is selected from the group consisting of palmitic acid, chlorogenic acid, and linoleic acid.
2. The pharmaceutical composition according to claim 1, wherein the antioxidant is present in an amount of 0.01 to 2% by weight based on the total weight of the composition.
3. The pharmaceutical composition according to claim 1, wherein the antioxidant is present in an amount of 0.1 to 1% by weight based on the total weight of the composition.
4. The pharmaceutical composition according to claim 1, wherein the antioxidant is present in an amount of 0.1% by weight based on the total weight of the composition.
5. The method of claim 1,

   8-12% by weight of efinaconazole;

   Ethanol 50-65% by weight;

   10 to 15% by weight of cyclomethicone;

   8-15% by weight of diisopropyl adipate;

   8-15% by weight of C ₁₂ -C _{15 alkyl lactate;}

   0.0001 to 1.5% by weight of ethylenediaminetetraacetic acid or its sodium salt;

   0.01 to 2% by weight of an antioxidant selected from the group consisting of palmitic acid, chlorogenic acid, and linoleic acid;

   From 0.05 to 0.25% by weight of citric acid; And

   0 to 5% by weight of water

   Pharmaceutical composition comprising a.
6. The method of claim 1,

   10% by weight efinaconazole;

   53.79975% ethanol by weight;

   13% by weight cyclomethicone;

   12% by weight of diisopropyl adipate;

   10% by weight of C ₁₂ -C _{15 alkyl lactate;}

   0.00025% by weight of ethylenediaminetetraacetic acid or sodium salt thereof;

   0.1% by weight of an antioxidant selected from the group consisting of palmitic acid, chlorogenic acid, and linoleic acid;

   0.1% citric acid; And

   1% by weight of water

   A pharmaceutical composition consisting of.